1474-14-2

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-2-[(3S,8S,9S,10R,13S,14S,17R)-3-(acetyloxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid (non-preferred name) is used as a pharmaceutical agent for hormone therapy due to its steroidal structure and potential to modulate hormonal activity.
Used in Drug Development Research:
This molecule is utilized in drug development research to explore its potential as a therapeutic agent for various conditions that may benefit from hormone regulation or modulation. Its unique structure and functional groups make it a candidate for further investigation into its pharmacological properties and efficacy.

Upstream product

• 55509-37-0 3β-acetoxy-23,24-bisnor-chol-5-en-22-ol 
• 2458-53-9 brassicasterol acetate 
• 566-77-8 hydroxybisnorcholenic acid 
• 108-24-7 acetic anhydride 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 19408-50-5 3β-Hydroxy-23,24-bisnorchol-5-en-22-oic Acid 
• 34751-25-2 3β-acetoxy-24-nor-chol-5-en-23-oic acid 
• 83-48-7 Stigmasterol 
• 4651-48-3 stigmasterol acetate 
• 10211-88-8 (20S)-3β-acetoxybisnorchol-5-en-22-al 
• 10211-88-8 (20S)-3β-acetoxybisnorchol-5-en-22-al 
• 4651-48-3 acetic acid stigmasteryl ester 
• 514-50-1 3β-acetoxy-5α,6β-dibromocholestane 

Downstream Products

• 58526-32-2 3β-acetoxy-20(S)-5α-bisnorcholanic acid 
• 67711-02-8 3β-acetoxy-23,24-dinorchol-5-en-22-oyl chloride 
• 288256-94-0 (S)-2-((3S,8S,9S,10R,13S,14S,17R)-3-Acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propionic acid 4-nitro-phenyl ester 
• 913338-69-9 5-[2-(3-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propionylamino]-pentanoic acid methyl ester 
• 913338-71-3 7-[2-(3-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propionylamino]-heptanoic acid methyl ester 
• 95305-07-0 (22E)-1α,3β-diacetoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)cholesta-6,22-dien-24-one 
• 95270-35-2 (22E,24R)-1α,3β-diacetoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)cholesta-6,22-dien-24-ol 
• 95270-35-2 (22E,24S)-1α,3β-diacetoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)cholesta-6,22-dien-24-ol 
• 95270-36-3 (22E,24R)-1α,3β-diacetoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)-cholesta-6,22-dien-24-ol 24-(+)-MTPA ester 
• 95270-36-3 (22E,24S)-1α,3β-diacetoxy-5α,8α-(3,5-dioxo-4-phenyl-1,2,4-triazolidino)-cholesta-6,22-dien-24-ol 24-(+)-MTPA ester 
• 95270-41-0 (22E,24R)-1α,24-dihydroxy-22-dehydrovitamin D₃ 
• 95270-42-1 (22E,24S)-1α,24-dihydroxy-22-dehydrovitamin D₃ 
• 1913-47-9 3β,20α-diacetoxypregn-5-ene 
• 72560-37-3 3-O-acetylpregna-5,20-dien-3β-ol 

Relevant academic research and scientific papers

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level S24(S)-hydroxycholesterol compared to a reference standard.

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.